CRABP2 and pancreatic ductal adenocarcinoma: Furthermore, CRABP2 is highly expressed in pancreatic ductal adenocarcinoma [30], breast cancer [31], and non-small cell lung cancer (NSCLC) [32], its high expression is associated with poor prognosis of patients with NSCLC or ER-negative breast cancer [32,33].